Mount Sinai & KSU Medical City Collaborate on IBD Research in Saudi Families OR IBD: New Study to Focus on Genetic Risk & Personalized Treatment OR Saudi-US Partnership to Advance IBD Biomarker Discovery & Early Diagnosis

A new research partnership between Mount Sinai Health System in New York City and King Saud University Medical City in Riyadh, Saudi Arabia, aims to unravel the complexities of familial inflammatory bowel disease (IBD). This three-year collaboration, announced on March 3, 2026, focuses on understanding why IBD – encompassing conditions like Crohn’s disease and ulcerative colitis – clusters in certain Saudi families, with the ultimate goal of improving early detection and personalized treatment strategies.

Unpacking Familial IBD: A Genetic and Environmental Puzzle

Inflammatory bowel disease is a chronic inflammatory condition affecting the digestive tract. While the exact causes remain elusive, it’s understood that a combination of genetic predisposition, immune system dysfunction and environmental factors play a role. Familial IBD, where multiple family members are affected, suggests a stronger genetic component, but the specific genes and how they interact with environmental triggers are still largely unknown. Understanding these factors is crucial, as IBD can significantly impact quality of life and, in some cases, lead to serious complications.

The project will concentrate on Saudi families with a history of IBD, analyzing clinical data and biological samples – including whole blood, serum, and stool – from affected individuals and their at-risk relatives. Mount Sinai will spearhead the advanced biomarker discovery and multi-omics analyses, leveraging state-of-the-art research tools to identify potential indicators of disease risk and progression. King Saud University Medical City will oversee participant enrollment and sample collection, capitalizing on its established network and expertise within the Saudi population. Mount Sinai Health System

The Power of ‘Multi-Omics’ in IBD Research

A key component of this collaboration is the use of “multi-omics” profiling. This approach involves analyzing different layers of biological information – including genomics (genes), transcriptomics (gene expression), proteomics (proteins), and metabolomics (metabolites) – to gain a comprehensive understanding of the biological processes underlying IBD. By integrating these diverse datasets, researchers hope to identify patterns and biomarkers that would be missed by studying only one “ome” at a time. Biomarkers are measurable indicators of a biological state or condition, and identifying them is crucial for early diagnosis and monitoring treatment response. News Medical

“Familial IBD is still poorly understood, even though families with several affected members can teach us a great deal about how these diseases develop,” explains Dr. Jean-Frédéric Colombel, Professor of Medicine (Gastroenterology) and Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at the Icahn School of Medicine at Mount Sinai. “What makes this collaboration exciting is the ability to study well-characterized families alongside comprehensive molecular data. That combination is rare, and it gives us a real chance to pinpoint early signals of disease.”

Why Focus on Saudi Families?

The decision to focus on Saudi families is strategic. IBD prevalence is rising globally, but rates vary significantly between populations. Saudi Arabia has a relatively high incidence of IBD, and the disease often presents with unique characteristics within the population. Studying families within this region allows researchers to control for shared genetic backgrounds and environmental exposures, making it easier to identify specific factors contributing to disease development. The close-knit nature of many Saudi families facilitates long-term follow-up and data collection.

Immune System Insights and Personalized Therapies

The research also aims to shed light on the role of the immune system in familial IBD. IBD is fundamentally an immune-mediated disease, meaning that the immune system mistakenly attacks the digestive tract, causing inflammation. By studying families with multiple affected members, researchers can track how immune responses change over time and identify factors that differentiate those who develop disease from those who remain healthy. This knowledge could pave the way for more targeted immunotherapies – treatments that modulate the immune system to reduce inflammation.

“Familial IBD gives us a rare opportunity to study the immune system in a context where genetics and environment are clearly interacting,” says Dr. Miriam Merad, Chair of Immunology and Immunotherapy at Mount Sinai. “When several people in the same family are affected, One can follow how immune signals shift over time and begin to understand why some relatives develop disease while others do not.”

Data Sharing and Translational Potential

A crucial aspect of this collaboration is the emphasis on structured data sharing and joint analyses. The project will create a unique resource of high-quality biospecimens linked with detailed clinical information and family pedigrees. This shared dataset will be invaluable for researchers around the world, accelerating the pace of discovery and fostering collaboration. The ultimate goal is to translate these findings into improved diagnostic tools and therapies for IBD patients globally.

According to Dr. Nahla Azzam, Professor of Medicine at King Saud University, “For families living with IBD, uncertainty can last for years – especially for relatives who worry they may be next. Familial clustering gives us a valuable opportunity to recognize earlier patterns of risk and disease activity.”

Looking Ahead: From Research to Clinical Practice

The initial three-year phase of the collaboration will focus on data collection, biomarker discovery, and preliminary analyses. Following this period, Mount Sinai and King Saud University Medical City may consider extending the partnership to pursue promising discoveries into translational studies – research that aims to bring laboratory findings into clinical practice. This could involve clinical trials to test new diagnostic tests or therapies. markets.financialcontent.com

Dr. Abdurahman Niazy, Director of the Prince Naif Bin Abdulaziz Health Research Center, emphasizes the commitment to precision medicine: “By combining KSUMC’s ability to identify and characterize high-risk familial cohorts with Mount Sinai’s advanced multi-omics and integrative biomarker discovery capabilities, we aim to define clearer biological signals that support earlier risk assessment and more precise, individualized treatment strategies.”

This collaboration represents a significant step forward in our understanding of familial IBD and holds promise for improving the lives of individuals and families affected by this challenging condition. The focus on a well-defined population, combined with cutting-edge research techniques, positions this project to deliver meaningful insights and more effective treatments.